Related Experiment Videos
Autoimmunity in dilated cardiomyopathy and the major histocompatibility complex
1Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.
International Journal of Cardiology
|May 1, 1996
Summary
Autoimmune responses, including autoantibodies against cardiac proteins, are implicated in some cases of dilated cardiomyopathy. Genetic markers like human leukocyte antigen (HLA) may indicate susceptibility to this immune-mediated heart condition.
Area of Science:
- Cardiology
- Immunology
- Genetics
Background:
- Dilated cardiomyopathy (DCM) is a complex heart condition affecting a subset of patients through autoimmune mechanisms.
- These mechanisms involve autoantibodies targeting cardiac proteins and dysregulated lymphocyte activity.
Purpose of the Study:
- To investigate the role of autoimmune processes in dilated cardiomyopathy pathogenesis.
- To identify potential genetic markers associated with immune-mediated myocardial damage in DCM.
Main Methods:
- Analysis of autoantibodies against cardiac proteins, specifically beta-adrenoceptors.
- Correlation with human leukocyte antigen (HLA) phenotypes and T-cell receptor haplotypes.
- Investigation of specific gene variations, such as histidine at position 36 in the HLA-DQ beta 1 gene.
Main Results:
- Autoantibodies against beta-adrenoceptors were found to correlate with specific HLA-DR4/1 phenotypes and T-cell receptor haplotypes.
- A specific genetic marker (histidine at position 36 of the HLA-DQ beta 1 gene) was associated with clinically apparent dilated cardiomyopathy.
Conclusions:
- Autoimmune mechanisms, particularly autoantibody production and lymphocyte regulation, are significant in a subgroup of DCM.
- Major histocompatibility complex (MHC) components may serve as predictive markers for susceptibility to immune-mediated myocardial damage in dilated cardiomyopathy.